Study S001544

Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02244164
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Masking: NONE
Status: TERMINATED
Enrollment: 5
Start: 2014-10
Primary completion: 2023-02-13
Lead sponsor: Erasme University Hospital
Conditions: Type 2 Diabetes; Incretinomimetics; Pancreas
Interventions: DRUG:Incretinomimetics; DRUG:DPP-4 inhibitors
Results posted: FALSE

Registered primary outcomes

Volumetric measurement of the pancreas [1 year]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0018468	A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? Butler PC, Diabetes care	2013	Other	PMID 23645885 DOI	registry reference RESULT:23645885
R0023824	Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Amori RE, JAMA	2007	Systematic review	PMID 17622601 DOI	registry reference RESULT:17622601
R0014170	The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Drucker DJ, Lancet (London, England)	2006	Narrative review	PMID 17098089 DOI	registry reference RESULT:17098089